Last reviewed · How we verify
Ciprofloxacin triple dose
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial infections (specific indication for triple-dose formulation in Phase 3 unknown; historically used for respiratory, urinary, gastrointestinal, and skin infections).
At a glance
| Generic name | Ciprofloxacin triple dose |
|---|---|
| Sponsor | Bayer |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ciprofloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The 'triple dose' designation likely refers to a higher dosing regimen being evaluated in Phase 3 trials, potentially for serious infections or resistant pathogens.
Approved indications
- Bacterial infections (specific indication for triple-dose formulation in Phase 3 unknown; historically used for respiratory, urinary, gastrointestinal, and skin infections)
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
- Tendinopathy/tendon rupture
- QT prolongation
- Photosensitivity
Key clinical trials
- A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults (PHASE3)
- BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin triple dose CI brief — competitive landscape report
- Ciprofloxacin triple dose updates RSS · CI watch RSS
- Bayer portfolio CI